Recent advances in nanotechnology for the treatment of metabolic syndrome

被引:12
作者
Bahadori, Effat [1 ]
Farjami, Zahra [2 ]
Rezayi, Majid [2 ,3 ,4 ]
Lngari, Hadis [2 ]
Darroudi, Majid [5 ]
Avan, Amir [2 ,3 ]
Ghayour-Mobarhan, Majid [2 ,3 ]
机构
[1] Mashhad Univ Med Sci, Dept Nutr, Fac Med, Mashhad, Razavi Khorasan, Iran
[2] Mashhad Univ Med Sci, Sch Med, Dept Modern Sci & Technol, Mashhad, Razavi Khorasan, Iran
[3] Mashhad Univ Med Sci, Sch Med, Metab Syndrome Res Ctr, Mashhad, Razavi Khorasan, Iran
[4] Mashhad Univ Med Sci, Med Toxicol Res Ctr, Mashhad, Razavi Khorasan, Iran
[5] Mashhad Univ Med Sci, Nucl Med Res Ctr, Mashhad, Razavi Khorasan, Iran
关键词
Metabolic syndrome; Treatment; Nanoparticles; CARDIOVASCULAR-DISEASE; DELIVERY-SYSTEM; NANOPARTICLES; NANOSPHERES; PREVALENCE; INSULIN; GLUCOSE; OBESITY; DESIGN; DAMAGE;
D O I
10.1016/j.dsx.2019.03.002
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Metabolic syndrome is a main clinical challenge of global health which is growing universally. It would be resulted from over-consumption of energy, increased obesity, and lack of movement during life. The metabolic syndrome causes a five-fold increase in the risk of type 2 diabetes mellitus and a double increase in the risk of rising cardiovascular disease over the next 5-10 years. Based on this, more attention has been drawn to the diagnosis and treatment options of this disease. Nanotechnology is one of the preferred methods for improving this disease. This way is a natural development in many health domains, including synthetic and nanostructures. The use of nanoparticles with the purpose of increase the effectiveness of treatment, decrease the side effects and the amount of drug usage, through their small size, permeability and maintenance strength lead to their absorption by target organs. Meanwhile, different nanoparticles with consumption values and particle size have been investigated. (c) 2019 Diabetes India. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:1561 / 1568
页数:8
相关论文
共 68 条
  • [1] Nanocarriers as treatment modalities for hypertension
    Alam, Tausif
    Khan, Saba
    Gaba, Bharti
    Haider, Md. Faheem
    Baboota, Sanjula
    Ali, Javed
    [J]. DRUG DELIVERY, 2017, 24 (01) : 358 - 369
  • [2] The metabolic syndrome - a new worldwide definition
    Alberti, KGMM
    Zimmet, P
    Shaw, J
    [J]. LANCET, 2005, 366 (9491) : 1059 - 1062
  • [3] Antidiabetic Activity of Zinc Oxide and Silver Nanoparticles on Streptozotocin- Induced Diabetic Rats
    Alkaladi, Ali
    Abdelazim, Aaser Mohamed
    Afifi, Mohamed
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2014, 15 (02): : 2015 - 2023
  • [4] Grundy Scott M, 2005, Crit Pathw Cardiol, V4, P198
  • [5] [Anonymous], 1923, Zentralblatt fuer Innere Medizin, DOI DOI 10.1002/(SICI)1096-9136(199807)15:7<539::
  • [6] Magnetic poly(D,L-lactide) nanoparticles loaded with aliskiren: A promising tool for hypertension treatment
    Antal, Iryna
    Kubovcikova, Martina
    Zavisova, Vlasta
    Koneracka, Martina
    Pechanova, Olga
    Barta, Andrej
    Cebova, Martina
    Antal, Vitaliy
    Diko, Pavel
    Zduriencikova, Martina
    Pudlak, Michal
    Kopcansky, Peter
    [J]. JOURNAL OF MAGNETISM AND MAGNETIC MATERIALS, 2015, 380 : 280 - 284
  • [7] Avogaro P., 1965, Diabetologia, V1, P137
  • [8] Cardiovascular risk factors in the elderly: the Tehran Lipid and Glucose Study
    Azizi, F
    Emami, H
    Salehi, P
    Ghanbarian, A
    Mirmiran, P
    Mirbolooki, M
    Azizi, T
    [J]. JOURNAL OF CARDIOVASCULAR RISK, 2003, 10 (01): : 65 - 73
  • [9] Thermosensitive pluronic micelles stabilized by shell cross-linking with gold nanoparticles
    Bae, Ki Hyun
    Choi, Seung Ho
    Park, Sung Young
    Lee, Yuhan
    Park, Tae Gwan
    [J]. LANGMUIR, 2006, 22 (14) : 6380 - 6384
  • [10] Balkau B, 1999, DIABETIC MED, V16, P442